SillaJen initiates phase 1/2 trial of Pexa-Vec in metastatic colon cancer
The study, led by Dr. Tim Greten at the National Cancer Institute (NCI), is being conducted as part of a Cooperative Research and Development Agreement (CRADA) with the
Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research.
The company has announced the top-line results from the Phase III KRONOS trial, which showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler
GEP-NET is a form of cancer that affects the pancreas or gastrointestinal tract. The approval is for adult patients with somatostatin receptor-positive GEP-NETs and it covers conditions like foregut, midgut,
This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced